Table 4.

Association of a mitochondrial PRS and mitochondrial haplogroups (model 1) and their interactions (model 2) with baseline risk of Alzheimer’s disease adjusting for PRS excluding nMT genes and APOE

Variable	Model 1			Model 2
	β^a	SE	p	β^a	SE	p
Age	0.001	0.02	0.953	0.01	0.02	0.686
Male	0.16	0.28	0.58	0.03	0.29	0.92
APOE status
ε4+	1.66	0.32	1.78E-07	1.72	0.33	2.20E-07
ε2+	−0.6	0.72	0.407	−0.74	0.74	0.312
PC1	−0.59	0.17	3.42E-04	−0.55	0.17	9.86E-04
PC2	0.84	0.69	0.224	0.69	0.7	0.327
PRS w/o nMT & APOE	3.26	0.33	1.05E-22	3.26	0.34	3.65E-22
nMT-PRS	0.42	0.17	0.012	0.68	0.24	0.004
Haplogroup
I	0.55	0.74	0.459	0.63	0.74	0.395
J	0.53	0.55	0.331	0.55	0.57	0.333
K	0.48	0.45	0.289	0.44	0.44	0.311
T	0.43	0.47	0.357	0.56	0.48	0.248
U	1.01	0.46	0.027	1.11	0.48	0.021
V	0.5	0.8	0.532	0.81	1.02	0.423
W	0.19	1.14	0.87	0.55	1.14	0.631
X	−0.29	1.23	0.813	−1.51	2.48	0.543
Haplogroup × nMT-PRS
I	-	-	-	−0.36	1.15	0.752
J	-	-	-	0.11	0.8	0.893
K	-	-	-	−0.9	0.46	0.052
T	-	-	-	−1.25	0.58	0.032
U	-	-	-	0.24	0.61	0.702
V	-	-	-	1.16	1.93	0.546
W	-	-	-	−1.02	0.99	0.305
X	-	-	-	−3.29	2.78	0.237

Key: APOE, apolipoprotein E; nMT-PRS, nuclear-encoded mitochondrial polygenic risk score; PC1, principal component 1; PC2, principal component 2.

Results in the main text are presented as the exponentiation of the beta.